Mica D. E. Glaun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mica D. E. Glaun has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Frederico Omar Gleber Netto
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 shared publications - Elsa R. Flores
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
2 shared publications - Jared K. Burks
Department of Leukemia, Division of Center Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2 shared publications - Kenneth Y. Tsai
H. Lee Moffitt Cancer Center and Research Institute 1 Cancer Biology and Evolution Program Tampa, Florida
2 shared publications - Moran Amit
Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2 shared publications - Padmanee Sharma
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 shared publications
Latest Publications
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-074-074
Abstract PO-074: The evolution of the tumor immune microenvironment in immunosuppressed patients with cutaneous squamous cell carcinoma
Immunosuppression is a major risk and prognostic factor for cutaneous squamous cell carcinoma (cSCC). Immune checkpoint inhibition is approved for the treatment of cSCC, yet most immunosuppressed patients are ineligible for immunotherapy. Better understanding on the tumor microenvironment of cSCC in the context of immunosuppression (i.e., organ transplant recipients, patients with hematological malignancies or autoimmune diseases or acquired immunodeficiencies such as HIV) is of utmost importance for proper implementation of immunotherapy as a therapeutic alternative for these patients. In this study, we characterized the immune cell phenotype of cSCC from immunocompetent (IC) and immunosuppressed (IS) patients treated at two Cancer Centers. We also compared the immune phenotype changes through the steps of skin carcinogenesis between IC and IS patients, and among individuals with distinct causes for immunosuppression. To evaluate the TME dynamics during tumorigenesis, we analyzed specimen of normal epithelium, keratinocytic intraepidermal neoplasia (including carcinoma in situ and actinic keratosis), or invasive cSCC. The analysis of cSCC tumor microenvironment was performed by multiplex immunofluorescence (Opal 12-Color), CyTOF and single-cell RNA sequencing. Our analysis revealed that densities of CD68+ and effector T-cells are diminished in IS patients compared with IC. An analysis of precursor lesions revealed that the density of tumoral CD8+LAG3+ T-cells in patients with hematological malignancies was significantly lower than in patients with other types of immunosuppression. Compared with patients with other types of immunosuppression, patients with hematological malignancies had a higher density of stromal CD4+ T cells in precursor lesions but a lower density of CD20+ B cells. Overall, IS patients had worse outcomes than IC patients, and the densities of CD68+ and CD8+LAG3+ cells were prognostic in this cohort. CD8+LAG3+ was significantly associated with DSS of IS patients indicating the impact of dysfunctional cytotoxic T cells on these patients’ survival. Our findings provide a detailed insight into the underlying immune alterations from tumor inception through growth and invasion, in patients with different types of immunosuppression. This dataset will serve as a benchmark data to guide clinical trials aiming to treat this patient population and provide a potential rationale for designing safer immunotherapy clinical trials for the population of IS patients with cSCC or other head and neck cancers. Citation Format: Mica D. E. Glaun, Frederico O. Gleber-Netto, Priyadharsini Nagarajan, Tongxin Xie, Shamima Akhter, Yu Han Chen, Erez Baruch N. Baruch, Michael K. Wong, Emily Y. Chu, Kenneth Y. Tsai, Elsa R. Flores, Deborah A. Silverman, Ryan P. Goepfert, Murat Cobanoglu, Jared Burks, Padmanee Sharma, James P. Allison, Jeffrey N. Myers, Neil D. Gross, Moran Amit. The evolution of the tumor immune microenvironment in immunosuppressed patients with cutaneous squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-074.
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-074-074
Open AccessAbstract PO-074: The evolution of the tumor immune microenvironment in immunosuppressed patients with cutaneous squamous cell carcinoma
Immunosuppression is a major risk and prognostic factor for cutaneous squamous cell carcinoma (cSCC). Immune checkpoint inhibition is approved for the treatment of cSCC, yet most immunosuppressed patients are ineligible for immunotherapy. Better understanding on the tumor microenvironment of cSCC in the context of immunosuppression (i.e., organ transplant recipients, patients with hematological malignancies or autoimmune diseases or acquired immunodeficiencies such as HIV) is of utmost importance for proper implementation of immunotherapy as a therapeutic alternative for these patients. In this study, we characterized the immune cell phenotype of cSCC from immunocompetent (IC) and immunosuppressed (IS) patients treated at two Cancer Centers. We also compared the immune phenotype changes through the steps of skin carcinogenesis between IC and IS patients, and among individuals with distinct causes for immunosuppression. To evaluate the TME dynamics during tumorigenesis, we analyzed specimen of normal epithelium, keratinocytic intraepidermal neoplasia (including carcinoma in situ and actinic keratosis), or invasive cSCC. The analysis of cSCC tumor microenvironment was performed by multiplex immunofluorescence (Opal 12-Color), CyTOF and single-cell RNA sequencing. Our analysis revealed that densities of CD68+ and effector T-cells are diminished in IS patients compared with IC. An analysis of precursor lesions revealed that the density of tumoral CD8+LAG3+ T-cells in patients with hematological malignancies was significantly lower than in patients with other types of immunosuppression. Compared with patients with other types of immunosuppression, patients with hematological malignancies had a higher density of stromal CD4+ T cells in precursor lesions but a lower density of CD20+ B cells. Overall, IS patients had worse outcomes than IC patients, and the densities of CD68+ and CD8+LAG3+ cells were prognostic in this cohort. CD8+LAG3+ was significantly associated with DSS of IS patients indicating the impact of dysfunctional cytotoxic T cells on these patients’ survival. Our findings provide a detailed insight into the underlying immune alterations from tumor inception through growth and invasion, in patients with different types of immunosuppression. This dataset will serve as a benchmark data to guide clinical trials aiming to treat this patient population and provide a potential rationale for designing safer immunotherapy clinical trials for the population of IS patients with cSCC or other head and neck cancers. Citation Format: Mica D. E. Glaun, Frederico O. Gleber-Netto, Priyadharsini Nagarajan, Tongxin Xie, Shamima Akhter, Yu Han Chen, Erez Baruch N. Baruch, Michael K. Wong, Emily Y. Chu, Kenneth Y. Tsai, Elsa R. Flores, Deborah A. Silverman, Ryan P. Goepfert, Murat Cobanoglu, Jared Burks, Padmanee Sharma, James P. Allison, Jeffrey N. Myers, Neil D. Gross, Moran Amit. The evolution of the tumor immune microenvironment in immunosuppressed patients with cutaneous squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-074.
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-049-049
Abstract PO-049: The neural landscape is associated with functional outcomes for patients with oropharyngeal squamous cell carcinoma
Despite the excellent prognosis of patients with oropharyngeal squamous cell carcinoma (OPSCC), long-term functional impairment (e.g., dysphagia) is a major burden for many patients. Recent studies have explored the role of pharyngeal constrictors and muscle fibrosis in dysphagia. However, to date, no study has examined the association between the OPSCC neural microenvironment and posttreatment functional impairment. We hypothesized that cancer-related neuronal changes in the OPSCC tumor microenvironment (TME) would affect patients’ prognoses. Therefore, in the present study, we investigated whether cancer-related changes in the tumor neuronal microenvironment influence functional outcomes in patients with OPSCC. Prospectively collected, patient-reported outcomes (i.e., from the MD Anderson Symptom Inventory [MDASI] and the MD Anderson Dysphagia Inventory [MDADI]) and functional outcomes from the Dynamic Imaging Grade of Swallowing Toxicity [DIGEST] for patients with OPSCC were collected (n=29). OPSCC tissue samples were obtained from surgically treated patients, and multiplex/high-plex immunofluorescence and machine learning techniques were used to correlate neuronal changes with prospectively collected patient data. Electromyography was performed to assess the neuronal populations involved in neuropathies after treatment. A murine animal model of dysphagia was also used to correlate the neuronal changes. The results showed that sensory nerves with adrenergic features (CGRP+TH+) were associated with perineural and lymphovascular invasion. In addition, we found that human papillomavirus associated OPSCC was associated with an enrichment of parasympathetic progenitors (VIP+DCX+). Poor MDASI scores were associated with CGRP+, adrenergic (TH+), or CGRP+TH+ innervation, and growing progenitor neurons (GAP43+DCX+) were associated with improved oral symptoms. Swallowing, measured by MDADI scale revealed that patients with tumors enriched with growing (GAP43+), parasympathetic (VIP+), and neuronal progenitor (DCX+) neurons reported poor swallowing perception; subgroup electromyography analysis confirmed our findings. Quantitative swallowing assessment with DIGEST by speech language pathologists revealed that TMEs innervated by CGRP+, TH+, and MBP+ neurons were associated with poor swallowing functions. Finally, using a murine model of dysphagia we confirmed that sensory (CGRP+), myelinated (MBP+), and cholinergic parasympathetic (CHAT+) or progenitor (CHAT+DCX+) enrichment was associated with denervation and downstream dysphagia. In conclusion, our results show that neuronal changes are correlated with clinical features in OPSCC patients. Patients’ functional outcomes after therapy completion are influenced by distinct nerve populations in the TME. These benchmark data should be further evaluated as a potential target for cancer survivors with dysphagia and as a biomarker for patients who might need escalated swallowing rehabilitation during and after treatment for OPSCC. Citation Format: Shajedul Islam, Frederico O. Gleber-Netto, Collin F. Mulcahy, Mica D. E. Glaun, Patrick J. Hunt, Michelle D. Williams, Carly E. Barbon, Weilu Zhao, Adewale Adebayo, Shamima Akhter, Tongxin Xie, Ismail Yaman, Jared K. Burks, Javier Gomez, Karin Woodman, Teresa E. Lever, Katherine A. Hutcheson, Moran Amit. The neural landscape is associated with functional outcomes for patients with oropharyngeal squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-049.
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-049-049
Open AccessAbstract PO-049: The neural landscape is associated with functional outcomes for patients with oropharyngeal squamous cell carcinoma
Despite the excellent prognosis of patients with oropharyngeal squamous cell carcinoma (OPSCC), long-term functional impairment (e.g., dysphagia) is a major burden for many patients. Recent studies have explored the role of pharyngeal constrictors and muscle fibrosis in dysphagia. However, to date, no study has examined the association between the OPSCC neural microenvironment and posttreatment functional impairment. We hypothesized that cancer-related neuronal changes in the OPSCC tumor microenvironment (TME) would affect patients’ prognoses. Therefore, in the present study, we investigated whether cancer-related changes in the tumor neuronal microenvironment influence functional outcomes in patients with OPSCC. Prospectively collected, patient-reported outcomes (i.e., from the MD Anderson Symptom Inventory [MDASI] and the MD Anderson Dysphagia Inventory [MDADI]) and functional outcomes from the Dynamic Imaging Grade of Swallowing Toxicity [DIGEST] for patients with OPSCC were collected (n=29). OPSCC tissue samples were obtained from surgically treated patients, and multiplex/high-plex immunofluorescence and machine learning techniques were used to correlate neuronal changes with prospectively collected patient data. Electromyography was performed to assess the neuronal populations involved in neuropathies after treatment. A murine animal model of dysphagia was also used to correlate the neuronal changes. The results showed that sensory nerves with adrenergic features (CGRP+TH+) were associated with perineural and lymphovascular invasion. In addition, we found that human papillomavirus associated OPSCC was associated with an enrichment of parasympathetic progenitors (VIP+DCX+). Poor MDASI scores were associated with CGRP+, adrenergic (TH+), or CGRP+TH+ innervation, and growing progenitor neurons (GAP43+DCX+) were associated with improved oral symptoms. Swallowing, measured by MDADI scale revealed that patients with tumors enriched with growing (GAP43+), parasympathetic (VIP+), and neuronal progenitor (DCX+) neurons reported poor swallowing perception; subgroup electromyography analysis confirmed our findings. Quantitative swallowing assessment with DIGEST by speech language pathologists revealed that TMEs innervated by CGRP+, TH+, and MBP+ neurons were associated with poor swallowing functions. Finally, using a murine model of dysphagia we confirmed that sensory (CGRP+), myelinated (MBP+), and cholinergic parasympathetic (CHAT+) or progenitor (CHAT+DCX+) enrichment was associated with denervation and downstream dysphagia. In conclusion, our results show that neuronal changes are correlated with clinical features in OPSCC patients. Patients’ functional outcomes after therapy completion are influenced by distinct nerve populations in the TME. These benchmark data should be further evaluated as a potential target for cancer survivors with dysphagia and as a biomarker for patients who might need escalated swallowing rehabilitation during and after treatment for OPSCC. Citation Format: Shajedul Islam, Frederico O. Gleber-Netto, Collin F. Mulcahy, Mica D. E. Glaun, Patrick J. Hunt, Michelle D. Williams, Carly E. Barbon, Weilu Zhao, Adewale Adebayo, Shamima Akhter, Tongxin Xie, Ismail Yaman, Jared K. Burks, Javier Gomez, Karin Woodman, Teresa E. Lever, Katherine A. Hutcheson, Moran Amit. The neural landscape is associated with functional outcomes for patients with oropharyngeal squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-049.
- 20 July 2022
- Published by Wiley in Advanced Biology
- Vol. 6 (9) , e2200053
Acetylcholine in Carcinogenesis and Targeting Cholinergic Receptors in Oncology
Tumor cells modulate and are modulated by their microenvironments, which include the nervous system. Accumulating evidence links the overexpression and activity of nicotinic and muscarinic cholinergic receptor subtypes to tumorigenesis in breast, ovarian, prostate, gastric, pancreatic, and head and neck cancers. Nicotinic and muscarinic receptors have downstream factors are associated with angiogenesis, cell proliferation and migration, antiapoptotic signaling, and survival. Clinical trials analyzing the efficacy of various therapies targeting cholinergic signaling or downstream pathways of acetylcholine have shed promising light on novel cancer therapeutics. Although the evidence for cholinergic signaling involvement in tumor development is substantial, a more detailed understanding of the acetylcholine‐induced mechanisms of tumorigenesis remains to be unlocked. Such an understanding would enable the development of clinical applications ranging from the identification of novel biomarkers to the utilization of existing drugs to modulate cholinergic signaling to the development of novel cancer therapies, as discussed in this review.
- 20 July 2022
- Published by Wiley in Advanced Biology
- Vol. 6 (9) , e2200053
Acetylcholine in Carcinogenesis and Targeting Cholinergic Receptors in Oncology
Tumor cells modulate and are modulated by their microenvironments, which include the nervous system. Accumulating evidence links the overexpression and activity of nicotinic and muscarinic cholinergic receptor subtypes to tumorigenesis in breast, ovarian, prostate, gastric, pancreatic, and head and neck cancers. Nicotinic and muscarinic receptors have downstream factors are associated with angiogenesis, cell proliferation and migration, antiapoptotic signaling, and survival. Clinical trials analyzing the efficacy of various therapies targeting cholinergic signaling or downstream pathways of acetylcholine have shed promising light on novel cancer therapeutics. Although the evidence for cholinergic signaling involvement in tumor development is substantial, a more detailed understanding of the acetylcholine‐induced mechanisms of tumorigenesis remains to be unlocked. Such an understanding would enable the development of clinical applications ranging from the identification of novel biomarkers to the utilization of existing drugs to modulate cholinergic signaling to the development of novel cancer therapies, as discussed in this review.
- Open Access
- 16 November 2021
- Published by Springer Nature in Research Square
The Tumor Microenvironment of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients
Nonmelanoma skin cancer is the most common malignancy and immunosuppression is a key risk factor. Despite the promising data demonstrating the efficacy of immune checkpoint inhibition in the treatment of cutaneous squamous cell carcinoma (cSCC), most immunosuppressed patients are not included in immunotherapy trials due to the risk for toxicity and the lack of data regarding cSCC immune landscape in immunosuppressed patients. To characterize the specific alterations accounting for a diminished antitumor immune response in immunosuppressed patients, we used multispectral imaging on cSCC pathology specimens from immunosuppressed patients with age and stage matched immunocompetent controls. We show that densities of CD68+ cells are diminished in immunosuppressed patients. Moreover, using an organ transplant recipient cohort from two cancer centers, we found significantly lower effector T-cells densities as compared with controls. Overall, density of CD68+ and CD8+LAG3+ cells were predictors of disease-specific and disease-free survival. These findings provide insight into the patterns of immune infiltrating cells in patients with different types of immunosuppression; leading us to conjecture that different immune based therapeutic approaches may be needed to treat immunosuppressed cSCC patients.
- 16 November 2021
- Published by Springer Nature in Research Square
Open AccessThe Tumor Microenvironment of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients
Nonmelanoma skin cancer is the most common malignancy and immunosuppression is a key risk factor. Despite the promising data demonstrating the efficacy of immune checkpoint inhibition in the treatment of cutaneous squamous cell carcinoma (cSCC), most immunosuppressed patients are not included in immunotherapy trials due to the risk for toxicity and the lack of data regarding cSCC immune landscape in immunosuppressed patients. To characterize the specific alterations accounting for a diminished antitumor immune response in immunosuppressed patients, we used multispectral imaging on cSCC pathology specimens from immunosuppressed patients with age and stage matched immunocompetent controls. We show that densities of CD68+ cells are diminished in immunosuppressed patients. Moreover, using an organ transplant recipient cohort from two cancer centers, we found significantly lower effector T-cells densities as compared with controls. Overall, density of CD68+ and CD8+LAG3+ cells were predictors of disease-specific and disease-free survival. These findings provide insight into the patterns of immune infiltrating cells in patients with different types of immunosuppression; leading us to conjecture that different immune based therapeutic approaches may be needed to treat immunosuppressed cSCC patients.